These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2957702)

  • 41. [New therapeutic possibilities in fulminant viral hepatitis].
    Weiland O; Ericzon BG; Andersson J; Hultcrantz R; Stiernstedt G
    Lakartidningen; 1989 Mar; 86(9):727-9. PubMed ID: 2522162
    [No Abstract]   [Full Text] [Related]  

  • 42. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation.
    Van Bömmel F; Schernick A; Hopf U; Berg T
    Gastroenterology; 2003 Feb; 124(2):586-7. PubMed ID: 12557178
    [No Abstract]   [Full Text] [Related]  

  • 43. [Update hepatitis D].
    Erhardt A; Starke C; Loerke J; Giesecke C; Heintges T; Häussinger D
    Med Klin (Munich); 2006 Mar; 101 Suppl 1():127-34. PubMed ID: 16802537
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Lamivudine therapy in patients with severe acute hepatitis B].
    Roznovský L; Orságová I; Kloudová A; Mrázek J
    Klin Mikrobiol Infekc Lek; 2007 Apr; 13(2):59-65. PubMed ID: 17599294
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Hepatitis A, B, C, D, E - What treatment options for whom?].
    Manns M
    Drug Res (Stuttg); 2014 Nov; 64 Suppl 1():S18-9. PubMed ID: 25423421
    [No Abstract]   [Full Text] [Related]  

  • 46. [Antiviral activity of phosphonoacetic acid, phosphonopropionic acid, and trisodium phosphonoformate hexahydrate against herpesvirus hominis type 1 and type 2 in vitro].
    Thiel KD; Wutzler P; Sprössig M; Bertram D
    Pharmazie; 1982 Aug; 37(8):608. PubMed ID: 6292963
    [No Abstract]   [Full Text] [Related]  

  • 47. [Bulevirtide for the treatment of hepatitis B with hepatitis D virus coinfection].
    Durmashkina E; Sarrazin C; Nitschmann S
    Inn Med (Heidelb); 2024 Jul; 65(7):746-748. PubMed ID: 38748277
    [No Abstract]   [Full Text] [Related]  

  • 48. HIV-1/hepatitis B coinfection.
    Benhamou Y
    Expert Rev Anti Infect Ther; 2005 Apr; 3(2):229-39. PubMed ID: 15918780
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Current Guidelines for treatment of hepatitis B. Correct diagnosis is the prerequisite.].
    Cornberg M; Manns MP
    Pharm Unserer Zeit; 2011 Jan; 40(1):45-51. PubMed ID: 21194082
    [No Abstract]   [Full Text] [Related]  

  • 50. Progress in the development of antiviral therapy for HTLV-III-associated diseases.
    Yarchoan R; Broder S
    Important Adv Oncol; 1987; ():293-311. PubMed ID: 2841232
    [No Abstract]   [Full Text] [Related]  

  • 51. The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients.
    Gaub J; Pedersen C; Poulsen AG; Mathiesen LR; Ulrich K; Lindhardt BO; Faber V; Gerstoft J; Hofmann B; Lernestedt JO
    AIDS; 1987 May; 1(1):27-33. PubMed ID: 2962590
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?
    Sheldon J; Ramos B; Toro C; Ríos P; Martínez-Alarcón J; Bottecchia M; Romero M; Garcia-Samaniego J; Soriano V
    Antivir Ther; 2008; 13(1):97-102. PubMed ID: 18389903
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Benign and fulminant HDV hepatitis in Greece.
    Papaevangelou GJ
    Prog Clin Biol Res; 1987; 234():395-402. PubMed ID: 3628396
    [No Abstract]   [Full Text] [Related]  

  • 54. Studies on the role of HDV in an outbreak of fulminant hepatitis in Bangui (Central African Republic).
    Lesbordes JL; Ravisse P; Georges AJ; Chevallier P; Pichoud C; Vitvitski L; Trepo C
    Prog Clin Biol Res; 1987; 234():451-9. PubMed ID: 3628412
    [No Abstract]   [Full Text] [Related]  

  • 55. Antiviral agents: the road from scepticism to efficacy.
    Galasso GJ
    Acta Microbiol Acad Sci Hung; 1981; 28(3):313-24. PubMed ID: 6171143
    [No Abstract]   [Full Text] [Related]  

  • 56. Treatment with telbivudine for fulminant hepatitis B.
    Lisotti A; Eusebi LH; Festi D; Bazzoli F; Mazzella G
    J Dig Dis; 2013 Nov; 14(11):619-21. PubMed ID: 23647670
    [No Abstract]   [Full Text] [Related]  

  • 57. Animal models for the understanding and control of HBV and HDV infections.
    Cova L; Fourel I; Vitvitski L; Lambert V; Chassot S; Hantz O; Trepo C
    J Hepatol; 1993; 17 Suppl 3():S143-8. PubMed ID: 8509630
    [No Abstract]   [Full Text] [Related]  

  • 58. Drugs recently released in Belgium. Foscarnet - pinacidil.
    Harvengt C
    Acta Clin Belg; 1991; 46(3):193-7. PubMed ID: 1656681
    [No Abstract]   [Full Text] [Related]  

  • 59. Fulminant liver failure from acute HCV superinfection in a patient with HIV, HBV, and HDV coinfections.
    Lee K; Smith PT
    AIDS Read; 2000 Jul; 10(7):398, 401. PubMed ID: 10932838
    [No Abstract]   [Full Text] [Related]  

  • 60. Severe hepatitis due to HBV-HDV coinfection.
    Zar T; Sharar Z; Mughal M; McClintock C
    Conn Med; 2001 Nov; 65(11):649-52. PubMed ID: 11766551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.